Biomarker Kinetics ™ : CA-125 KELIM ™ Calculator in Ovarian Cancer & Other Biomarkers

Changes in serum cancer biomarkers can indicate the effectiveness of treatment. Mathematical modeling makes it possible to calculate the mathematical equations describing longitudinal changes in cancer biomarkers over time. A kinetic approach based on a population model is of high interest because it allows the determination of individual parameters of kinetic profiles based on a few time points, with limited influence of inter- and intra-individual variability of time points and tests.

Our Tools

The Team

The models were developed by Team 3 of EA3738 CICLY of Lyon University (Université Claude Bernard Lyon 1, France) and Lyon University Hospital (Hospices Civils de Lyon, France), in collaboration with the collaborative French GINECO Group, under the supervision of Prof Benoit You MD PhD. The internet site and the smartphone application were developed with the support of HCL Fondation.

More about the team >
Université Claude Bernard Lyon 1 HCL Fondation HCL

BK™ Smartphone App

Biomarker-Kinetics.org™ also works on your smartphone!

To add it to your home screen:

  1. 1
    Open Safari or Chrome
  2. 2

    tap the icon in Safari browser or
    tap the icon in Chrome browser

  3. 3
    Select "Add to Home Screen"

Interested in collaboration for your datasets or your innovative drugs ? So are we!

Learn more >

News

The interface of your CA-125 calculator has been improved !
2026-03-04

The interface of your CA-125 calculator has been improved !

The interface of the CA-125 KELIM calculator has been redesigned to facilitate the selection of chemotherapy administration dates and CA-125 dates/values. Dictation is also now possible! Please do not hesitate to report any functional issues or share your feedback with us at biomarkers.kinetics@univ-lyon1.fr In the case of issue, you can use the previous version on https://legacy.biomarker-kinetics.org

KELIM cited in the recent ASCO guidelines for neo-adjuvant chemotherapy !
2025-01-31

KELIM cited in the recent ASCO guidelines for neo-adjuvant chemotherapy !

The updated ASCO guidelines about the management of patients treated with neo-adjuvant chemotherapy have just been published in https://ascopubs.org/doi/10.1200/JCO-24-02589 KELIM is cited as an indicator of the neo-adjuvant chemotherapy efficacy !

More >
Salvovar logo

Learn more about the future European clinical phase III trial SALVOVAR, where the patients with unfavorable KELIM score < 1.0 and a disease not amenable to complete interval debulking surgery after 3 to 4 cycles standard neo-adjuvant chemotherapy will be randomized to the continuation of the standard 3-weekly regimen, or a salvage regimen with weekly dose-dense carboplatin-paclitaxel

Visit website >